Does hyperinsulinemia and insulin resistance suppress hepatic SHBG and increase bioavailable sex steroids?

The metabolic state of the liver serves as a central regulator of sex hormone bioavailability. In individuals with insulin resistance, the liver's production of sex hormone-binding globulin (SHBG) is significantly impaired, leading to a cascade of hormonal shifts that affect tissue-level signaling.

Hepatic mechanisms of SHBG suppression

The reduction of SHBG in response to hyperinsulinemia is a direct, molecularly defined process occurring within hepatocytes.

• Transcriptional Repression: Research indicates that insulin resistance drives the activation of sterol regulatory element-binding proteins (SREBP-1c). These proteins repress the expression of hepatocyte nuclear factor 4-alpha (HNF-4α), which is the primary transcription factor required to activate the SHBG gene.
• Correlation with Liver Fat: Clinical studies, such as the Maastricht Study, have demonstrated that SHBG levels are inversely proportional to intrahepatic lipid content. In states of selective hepatic insulin resistance, the liver continues to synthesize lipids while failing to produce SHBG, making low SHBG a robust biomarker for hepatic steatosis and systemic metabolic dysfunction.

Alterations in steroid bioavailability and signaling

Reduced SHBG levels fundamentally shift the distribution of circulating sex hormones, increasing the proportion of "free" or bioavailable steroids.

• Free Hormone Hypothesis: Because SHBG has a high affinity for testosterone and estradiol, a decrease in its concentration results in a larger fraction of these hormones remaining unbound. For example, in postmenopausal women, low SHBG is associated with a significantly higher Free Androgen Index (FAI), often increasing the bioavailable testosterone fraction by 50–100%.
• Tissue Signaling Pathways: Beyond simple diffusion of free hormones into cells, SHBG modulates signaling through its own membrane receptor (R_SHBG), which can trigger non-genomic pathways involving cAMP and calcium flux. Consequently, when SHBG levels drop, tissues like the breast and endometrium are exposed to higher levels of free estrogen and altered SHBG-mediated signaling, which is associated with increased risks for hormone-sensitive pathologies.

Bottom line

Hyperinsulinemia and insulin resistance directly suppress hepatic SHBG production by downregulating the HNF-4α transcription factor. This reduction increases the circulating fraction of free, bioavailable sex steroids and alters tissue-level signaling, effectively serving as a link between metabolic health and endocrine function.